

## Two-year post-doctoral position in Bordeaux

A two-year post-doctoral position is available in Bordeaux in the group of Jean Rosenbaum (University of Bordeaux and INSERM). The team has discovered the overexpression of the two related proteins Pontin (RUVBL1) and Reptin (RUVBL2) in hepatocellular carcinoma (1, 2), shown that they are major determinants of tumor growth and viability, and that they may be targeted for therapy (3-5). The future project aims at better understanding the functions of these proteins in cell regulation, based notably on the functional investigation of genes that are regulated by Reptin and/or Pontin.



Starting time is from mid-October 2013. The candidate should hold a PhD at the time of beginning. He/she should be able of independent thinking and have an excellent training in cellular and molecular biology resulting in publication(s). Autonomy in cell culture, transfection, cloning, real-time PCR and basic biochemistry techniques (electrophoresis, western blot) is required. An experience in chromatin immunoprecipitation and/or analysis of transcriptomic data would be a plus. An experience in the field of cancer is welcome but not mandatory. We are looking for a hard working candidate with a strong deal of scientific curiosity.

French and foreign applicants are welcome. For non-French speakers, fluent English is required.

More information can be found in our recent reviews (6, 7) and on the team website: <http://www.gref-bordeaux.fr/en/RepTeam>

Applicants should send their CV, publication list, a cover letter outlining the significance of their previous research and their motivations, their date of availability, and the names and contact information from at least two references to Jean Rosenbaum: [jean.rosenbaum@inserm.fr](mailto:jean.rosenbaum@inserm.fr)

1. Haurie V, Menard L, Nicou A, Touriol C, Metzler P, Fernandez J, Taras D, et al. Adenosine triphosphatase pontin is overexpressed in hepatocellular carcinoma and coregulated with reptin through a new posttranslational mechanism. *Hepatology* 2009;50:1871-1883.
2. Rousseau B, Menard L, Haurie V, Taras D, Blanc J, Moreau-Gaudry F, Metzler P, et al. Overexpression and role of the ATPase and putative DNA helicase RuvB-like 2 in human hepatocellular carcinoma. *Hepatology* 2007;46:1108-1118.
3. Elkaim J, Castroviejo M, Bennani D, Taouji S, Allain N, Laguerre M, Rosenbaum J, et al. First identification of small molecule inhibitors of Pontin by combining virtual screening and enzymatic assay. *Biochem J* 2012;443:449-459.
4. Grigoletto A, Neaud V, Allain-Courtois N, Lestienne P, Rosenbaum J. The ATPase activity of reptin is required for its effects on tumor cell growth and viability in hepatocellular carcinoma. *Mol Cancer Res* 2013;11:133-139.
5. Menard L, Taras D, Grigoletto A, Haurie V, Nicou A, Dugot-Senant N, Costet P, et al. In vivo silencing of Reptin blocks the progression of human hepatocellular carcinoma in xenografts and is associated with replicative senescence. *J Hepatol* 2010;52:681-689.
6. Grigoletto A, Lestienne P, Rosenbaum J. The multifaceted proteins Reptin and Pontin as major players in cancer. *Biochim Biophys Acta* 2011;31:91-103.
7. Rosenbaum J, Baek SH, Dutta A, Houry WA, Huber O, Hupp TR, Matias PM. The emergence of the conserved AAA+ ATPases Pontin and Reptin on the signaling landscape. *Sci Signal* 2013;6:mr1.